Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA–TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract

References

1. Bahrani F. K., Mobley H. L. T. 1994; Proteus mirabilis MR/P fimbrial operon: genetic organization, nucleotide sequence, and conditions for expression. J Bacteriol 176:3412–3419[PubMed]
   [Google Scholar]
2. Bullas L. R., Ryu J. I. 1983; Salmonella typhimurium LT2 strains which are r− m+ for all three chromosomally located systems of DNA restriction and modification. J Bacteriol 156:471–474[PubMed]
   [Google Scholar]
3. Bullock W. O., Fernandez J. M., Short J. M. 1987; XL1-Blue: a high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection. Biotechniques 5:376–379
   [Google Scholar]
4. Chabalgoity J. A., Khan C. M., Nash A. A., Hormaeche C. E. 1996; A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8–23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection. Mol Microbiol 19:791–801 [View Article][PubMed]
   [Google Scholar]
5. Khan C. M., Villarreal-Ramos B., Pierce R. J., Riveau G., Demarco de Hormaeche R., McNeill H., Ali T., Fairweather N., Chatfield S. et al. 1994; Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella . Proc Natl Acad Sci U S A 91:11261–11265 [View Article][PubMed]
   [Google Scholar]
6. Li X., Lockatell C. V., Johnson D. E., Lane M. C., Warren J. W., Mobley H. L. T. 2004; Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis . Infect Immun 72:66–75 [View Article][PubMed]
   [Google Scholar]
7. Mobley H. L. T. 1997; Vaccines against Escherichia coli and Proteus urinary infections. In New Generation Vaccines pp. 931–944 Edited by Levine M. M., Woodrow G. C., Kaper J. B., Cobon G. S. New York: Marcel Dekker;
   [Google Scholar]
8. Mobley H. L. T., Belas R. 1995; Swarming and pathogenicity of Proteus mirabilis in the urinary tract. Trends Microbiol 3:280–284 [View Article][PubMed]
   [Google Scholar]
9. Nicolle L. E. 2005; Catheter-related urinary tract infection. Drugs Aging 22:627–639 [View Article][PubMed]
   [Google Scholar]
10. Nielubowicz G. R., Mobley H. L. T. 2010; Host-pathogen interactions in urinary tract infection. Nat Rev Urol 7:430–441 [View Article][PubMed]
    [Google Scholar]
11. Pellegrino R., Galvalisi U., Scavone P., Sosa V., Zunino P. 2003; Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol 36:103–110 [View Article][PubMed]
    [Google Scholar]
12. Pickett T. E., Pasetti M. F., Galen J. E., Sztein M. B., Levine M. M. 2000; In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun 68:205–213 [View Article][PubMed]
    [Google Scholar]
13. Renegar K. B., Small P. A. Jr, Boykins L. G., Wright P. F. 2004; Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978–1986[PubMed] [CrossRef]
    [Google Scholar]
14. Roberts J. A., Fussell E. N., Kaack M. B. 1990; Bacterial adherence to urethral catheters. J Urol 144:264–269[PubMed]
    [Google Scholar]
15. Roberts M., Bacon A., Li J., Chatfield S. 1999; Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C. Infect Immun 67:3810–3815[PubMed]
    [Google Scholar]
16. Sambrook J., Fritsch E. F., Maniatis T. 1989 Molecular Cloning: a Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
    [Google Scholar]
17. Scavone P., Sosa V., Pellegrino R., Galvalisi U., Zunino P. 2004; Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect 6:853–860 [View Article][PubMed]
    [Google Scholar]
18. Scavone P., Miyoshi A., Rial A., Chabalgoity A., Langella P., Azevedo V., Zunino P. 2007; Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice. Microbes Infect 9:821–828 [View Article][PubMed]
    [Google Scholar]
19. Scavone P., Rial A., Umpierrez A., Chabalgoity A., Zunino P. 2009; Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract. Microbiol Immunol 53:233–240 [View Article][PubMed]
    [Google Scholar]
20. Stamm W. E., Martin S. M., Bennett J. V. 1977; Epidemiology of nosocomial infections due to Gram-negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis 136:Suppl.S151–S160 [View Article]
    [Google Scholar]
21. Susskind M. M., Botstein D. 1978; Molecular genetics of bacteriophage P22. Microbiol Rev 42:385–413[PubMed]
    [Google Scholar]
22. Wang S., Li Y., Shi H., Scarpellini G., Torres-Escobar A., Roland K. L., Curtiss R. III 2010; Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun 78:3258–3271 [View Article][PubMed]
    [Google Scholar]
23. Warren J. W., Tenney J. H., Hoopes J. M., Muncie H. L., Anthony W. C. 1982; A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146:719–723 [View Article][PubMed]
    [Google Scholar]
24. Zunino P., Geymonat L., Allen A. G., Legnani-Fajardo C., Maskell D. J. 2000; Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol Med Microbiol 29:137–143 [View Article][PubMed]
    [Google Scholar]